Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mankind PharmaBOM:543904 +0.49%91 PB Ratio is 6.08 as of Aug. 31, 2026, which is 23% below its 10-year median of 7.90. GuruFocus rates BOM:543904 with a GF Score™ of 91/100 and a GF Value™ of ₹2,964.25 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 920 Drug Manufacturers companies, Mankind Pharma ranks worse than 86.74% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-08-31), Mankind Pharma's share price is ₹2399.00. Mankind Pharma's Book Value per Share for the quarter that ended in Jun. 2026 was ₹394.85. Hence, Mankind Pharma's PB Ratio of today is 6.08.
Warning Sign:
Mankind Pharma Ltd stock PB Ratio (=6.05) is close to 1-year high of 6.69.
The historical rank and industry rank for Mankind Pharma's PB Ratio or its related term are showing as below:
BOM:543904'
s PB Ratio Range Over the Past 10 Years
Min: 5.06 Med: 7.9 Max: 10.9
Current: 6.05
During the past 7 years, Mankind Pharma's highest PB Ratio was 10.90. The lowest was 5.06. And the median was 7.90.
BOM:543904's PB Ratio is ranked worse than 86.74% of 920
companies
in the Drug Manufacturers industry
Industry Median: 1.98
vs BOM:543904: 6.05
During the past 12 months, Mankind Pharma's average Book Value Per Share Growth Rate was 13.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 28.60% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 28.30% per year.
During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of Mankind Pharma was 31.20% per year. The lowest was 25.60% per year. And the median was 28.65% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Mankind Pharma PB Ratio Related Terms
Mankind Pharma PB Ratio Historical Data
* Premium members only.
The historical data trend for Mankind Pharma's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Mankind Pharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mankind Pharma PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Mankind Pharma's PB Ratio distribution charts can be found below:
* The bar in red indicates where Mankind Pharma's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Mankind Pharma's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Mankind Pharma (BOM:543904) has a PB Ratio of 6.08 as of Aug. 31, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Mankind Pharma and its competitors. This is 23% below median its historical median of 7.90. Over the past decade, Mankind Pharma's PB Ratio has ranged from 5.06 to 10.90. According to the industry distribution chart, Mankind Pharma ranks #798 out of 920 companies in the Drug Manufacturers industry, placing it in the top 86.7%.
Is Mankind Pharma's PB Ratio too high?
Mankind Pharma's current PB Ratio of 6.08 is 23% below median its 10-year median of 7.90. Over the past 10 years, this metric has ranged from a low of 5.06 to a high of 10.90. The Drug Manufacturers industry median PB Ratio is 1.98. Mankind Pharma's value of 6.08 is 207.1% above this industry median. Based on the distribution chart, Mankind Pharma ranks #798 out of 920 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Mankind Pharma has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Mankind Pharma's PB Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Mankind Pharma ranks #798 out of 920 companies for PB Ratio. This places Mankind Pharma in the lower half of its industry. The industry median PB Ratio is 1.98. Mankind Pharma's value of 6.08 is 207.1% above this benchmark. Historically, Mankind Pharma's own PB Ratio has ranged from 5.06 to 10.90 over the past decade. While the company's 10-year median is 7.90 vs. the industry median of 1.98, Mankind Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.98, based on 920 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mankind Pharma's current PB Ratio of 6.08 is 207.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Mankind Pharma and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mankind Pharma's current PB Ratio is 6.08, which is 23% below median its own 10-year median of 7.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mankind Pharma stock overvalued right now?
Based on GuruFocus' analysis, Mankind Pharma (BOM:543904) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹2,964.25, compared to a current price of ₹2,399.00 — trading 19.1% below its estimated fair value. The current PB Ratio is 6.08, which is 23% below median its 10-year median of 7.90 and 207.1% above the Drug Manufacturers industry median of 1.98. Mankind Pharma's overall GF Score™ is 91/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Mankind Pharma (BOM:543904), the current PB Ratio is 6.08 as of Aug. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mankind Pharma (BOM:543904) Overvalued in 2026?
Based on GuruFocus' analysis, Mankind Pharma stock appears to be undervalued.
The current stock price of ₹2,399.00 is trading 19.1% below its estimated GF Value™ of ₹2,964.25.
GuruFocus considers Mankind Pharma to be Modestly Undervalued.
Key valuation signals for BOM:543904:
PB Ratio: 6.08 (23% below median its 10-year median of 7.90)
GF Value™: ₹2,964.25 vs. price of ₹2,399.00 (19.1% below fair value)
Industry Position: 207.1% above the Drug Manufacturers median (#798 of 920)
No single metric tells the full story. See the BOM:543904 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mankind Pharma Ltd is engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. It operates at the intersection of Indian pharmaceutical formulations and consumer healthcare sectors providing products at affordable prices and has an established track record of building and scaling brands in-house. The company's brands include Manforce, Prega News, Gas-O-Fast, AcneStar and HealthOK. Geographically, the company derives a majority of its revenue from the sale of pharmaceutical products in India and the rest from its customers located outside India.
91GF Score
Get the complete analysis for BOM:543904
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543904 has been successfully added to your 
